
==== Front
J Hematol
J Hematol
Elmer Press
Journal of Hematology
1927-1212
1927-1220
Elmer Press

10.14740/jh1298
Review
Hemophilia and Other Congenital Coagulopathies in Women
Hemophilia in Women
Green David
Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA. Email: dgreenis1020@gmail.com
8 2024
31 8 2024
13 4 137141
8 6 2024
10 7 2024
Copyright 2024, Green
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Deficiencies of factor VIII (FVIII)/von Willebrand factor (VWF) or factor IX (FIX) are underappreciated as potential reasons for heavy menstrual bleeding, recurrent nosebleeds, and easy bruising in girls and women. Bleeding is usually not attributed to hemophilia because clinically significant deficiencies in clotting factors VIII and IX are thought to only affect males. While severe hemophilia is more commonly observed in boys and men, women with mutations in the FVIII or FIX genes (f8 or f9) may have widespread bruising and even joint bleeding. They might be heterozygotes with a hemophilic allele on one X chromosome and a normal allele on the other or rarely homozygotes with hemophilic alleles on both X chromosomes. If most or all of an X chromosome is missing (X-chromosome hemizygosity or Turner syndrome) and a hemophilic mutation is present on the other X chromosome, the affected woman will have a severe bleeding tendency. Other inherited disorders that affect women as well as men are von Willebrand disease, combined deficiencies of factor V (FV) and FVIII, and combined deficiencies of the vitamin K-dependent clotting factors. Women as well as men with autoimmune diseases or even those previously well might acquire a severe hemorrhagic disorder due to autoantibodies directed against FVIII, FIX, or VWF. Lastly, easy bruising and mildly decreased FVIII levels are occasionally observed in both men and women with hypothyroidism or panhypopituitarism. The purpose of this brief review is to increase clinician awareness that these bleeding disorders can affect girls and women. An accurate diagnosis and appropriate therapy will greatly benefit patients and their families.

Female hemophilia
Hemophilia heterozygotes
X-chromosome hemizygosity
Autoimmune hemophilia
None to declare.
==== Body
pmcIntroduction

Hemophilia, an inherited bleeding disorder, is due to a deficiency or defect in clotting factors VIII (FVIII) or IX (FIX). FVIII hemophilia (hemophilia A, classical hemophilia) occurs in 1 in 5,000 male births and FIX hemophilia (hemophilia B, Christmas disease) in 1 in 30,000 [1]. The genes governing the synthesis of these proteins reside on the X chromosome; when they are mutated, the bleeding phenotype is infrequently expressed in females because they have an unmutated allele on their other X chromosome, i.e., they are heterozygous. However, there are reports of female infants and young girls who bruise easily, have nose, gum, and joint bleeding, and laboratory evaluation discloses FVIII or FIX levels clearly below the normal range (50% to 150%). A factor level < 40% was reported in 1,976 females attending US Hemophilia Treatment Centers between 2012 and 2022 [2]. They represented 6.5% of the individuals seen at the centers; most (69%) were deficient in FVIII. Severe and moderately severe hemophilia, defined by factor levels ≤ 0.05 IU/mL, were noted in 8% of those with FVIII deficiency and 4.6% of those with FIX deficiency. Potential diagnoses in these girls and women are listed in Table 1, and a definitive review of the genetic causes of hemophilia in females was published by Miller et al in 2021 [3].

Table 1 Disorders Associated With FVIII or FIX Deficiency Affecting Girls and Women

Heterozygosity or hemizygosity for one or more hemophilic alleles	
Homozygosity or compound heterozygosity	
X-chromosome hemizgosity	
Acquired hemophilia due to a FVIII or FIX autoantibodya	
von Willebrand diseasea	
Acquired von Willebrand syndromea	
Combined FV/FVIII deficiencya, combined deficiency of all vitamin K-dependent factorsa	
Hypothyroidisma and panhypopituitarisma	
aThese disorders also affect boys and men. FVIII: factor VIII; FIX: factor IX.

Hemophilia Heterozygotes (Carriers)

Heterozygous females have a hemophilic allele on one X chromosome and a normal allele on the other X chromosome. Their fathers have hemophilia, or their mothers have hemophilic sons or other close relatives affected by this disorder. In the absence of a family history, targeted high-throughput gene sequencing will usually reveal f8 or f9 mutations [4]. A recent review estimated that there are as many as 96,000 women who are heterozygous for hemophilia A (FVIII deficiency) in the USA [5].

How likely is a bleeding tendency in these heterozygotes? Random inactivation of one of the X chromosomes in each cell (the Lyon hypothesis [6]) predicts that heterozygotes should have half the normal amount of FVIII or FIX, i.e., 0.5 IU/mL. However, the distribution of clotting factor levels in heterozygotes is described by a bell-shaped curve; in one survey of 1,528 heterozygotes for hemophilia A, 532(35%) had FVIII levels < 0.4 IU/mL [7]. In these individuals, skewing of X chromosome inactivation (extreme lyonization) results in clotting factor concentrations low enough to be associated with a bleeding phenotype [8]. Miller et al [3] describe several other circumstances that could account for the inactivation of the X chromosome bearing the normal allele and expression of only the hemophilic allele. A survey performed by Lusher et al [9] reported 10 FVIII heterozygotes with FVIII levels of 0.01 - 0.09 IU/mL, and six FIX heterozygotes with values of 0.02 - 0.1 IU/mL. All 16 had excessive bruising and several had hemarthroses. While epistaxis, easy bruising, and excessive bleeding with trauma regularly occur in hemophilic males with levels of 0.02 to 0.05 IU/mL, most of those having more than 0.05 IU/mL are asymptomatic. On the other hand, female heterozygotes with levels that are higher than 0.1 IU/mL often have heavy menstrual bleeding, postpartum hemorrhages, and other bleeding phenomena including hemarthroses [10-12]. Thus, in these girls and women, the level of clotting factor is not always an accurate predictor of bleeding [5].

Homozygosity and Compound Heterozygosity

If a father has hemophilia and the mother is a heterozygote, and the mother’s hemophilic allele is passed on to their daughter, she will be homozygous if the parent’s hemophilic mutations are concordant and a compound heterozygote if they are discordant. Miller et al [3] observed that compound heterozygosity can also occur when a hemophilia allele was inherited from one parent and a de novo mutated X chromosome was received from the other parent and provided several examples from the literature.

Homozygosity in a girl with severe hemophilia was reported as early as 1951 [13]. In another family, marriage between first cousins gave rise to daughters with hemorrhagic symptoms and FVIII levels less than 1% of normal; laboratory studies excluded von Willebrand disease (VWD) [14]. However, it is difficult to exclude carriership with severely skewed X-chromosome inactivation or X-chromosome deletions in these and other examples of female hemophilia reported in the older literature [15, 16]. Detailed genetic analyses are required to achieve an accurate diagnosis and identify asymptomatic family members who might be heterozygous for hemophilic mutations. In some cases, formal investigation of paternity might reveal a father affected by hemophilia.

X-Chromosome Hemizygosity

Hemizygosity describes individuals lacking all or most of an X chromosome. Turner syndrome is characterized by short stature, sexual immaturity, neck webbing, and a genetic profile of 45,X or 45,X/46,XX. Because the intact X chromosome comes from the mother in two-thirds of these individuals, a woman heterozygous for a hemophilic allele is likely to pass it on to her infant with Turner syndrome. Therefore, a bleeding phenotype might be anticipated in a female infant with Turner syndrome and a family history of hemophilia. Blag et al [17] describe the clinical and genetic features of 10 females with concomitant Turner syndrome and hemophilia. All had hemizygosity for the X chromosome or mosaic karyotypes; six had a serious bleeding disorder and the mutations detected in three of the six were intron 22 inversions characteristic of severe hemophilia.

Very low levels of FVIII and recurrent hemarthroses were reported in a girl with an aneuploid number of chromosomes (45/46) whose mother was a known hemophilia heterozygote; whether the X chromosome with the hemophilic allele was the only viable X chromosome in that patient was not established [18]. Nisen et al [19] described a female infant with ecchymoses, epistasis, and hemarthrosis. Her mother’s identical twin sister had a son with severe FIX deficiency hemophilia. Studies revealed that the propositus had non-random inactivation of a structurally abnormal X chromosome, resulting in the expression of a hemophilic FIX gene on the other, structurally normal X chromosome.

Severe hemophilia was reported in a young woman whose father was similarly affected [20]. She inherited a microdeletion (2.3 Mb at Xp22.2) in one of her X chromosomes from an otherwise normal mother, resulting in the extreme skewing of X-inactivation possibly due to a survival disadvantage or cell-lethal mechanism. The girl had a bleeding disorder because the only X chromosome expressed in her cells was derived from her hemophilic father.

Acquired Hemophilia due to FVIII or FIX Autoantibodies

Rarely, pathogenic autoantibodies develop in women (and men) without a previous history of a bleeding disorder. FVIII autoantibodies have occurred in association with other autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus and have arisen during pregnancy and the postpartum period. New onset bruising and bleeding in a girl or woman, along with a markedly reduced level of FVIII or FIX, should raise suspicion of this diagnosis. Lulla et al [21] described a woman with severe postpartum hemorrhage associated with a FVIII autoantibody; transplacental transfer of this antibody to the newborn caused excessive bleeding after a minor surgical procedure.

VWD

A decreased level of FVIII in females is more commonly due to VWD than hemophilia. Normally, the von Willebrand factor (VWF) forms a complex with FVIII, prolonging its clearance from the circulation. When the VWF is deficient or defective, the formation of this FVIII/VWF complex is impaired and the half-life of FVIII is shortened, resulting in variably reduced levels of the clotting factor. In the most severe form of VWD, type 3, individuals have no detectable VWF, and FVIII levels are less than 0.1 IU/mL. Another variant, type 2N (Normandy), has mutations affecting the FVIII binding site within the VWF N-terminal D’D3 domain; the FVIII deficiency that results is in the mild to moderate range. Patients with VWD bruise easily and their frequent epistaxis and heavy menstrual bleeding contribute to the development of iron-deficiency anemia. While bleeding in most patients is controlled by desmopressin infusions, VWF concentrates are required for those with type 2N or type 3 disease.

Acquired VWD

Individuals with systemic lupus erythematosus, monoclonal gammopathies, and lymphoproliferative syndromes can develop autoantibodies to VWF [22]. The clearance of antibodies bound to VWF/FVIII reduces the levels of both VWF and FVIII and can be differentiated from a synthetic defect in VWF by noting an increase in the ratio of VWF propeptide to VWF antigen [23]. Patients with autoantibodies to VWF have mucosal bleeding, and there is often excessive blood loss complicating surgery or trauma. Modalities for controlling bleeding include desmopressin, FVIII/VWF concentrates, and intravenous immunoglobulin. A few other causes of acquired von Willebrand syndrome (aVWS) are hypothyroidism (see below), Wilms tumor, aortic stenosis, and myeloproliferative disorders.

Combined FV and FVIII Deficiency/Combined Vitamin K-Dependent Factor Deficiency

Mutations in either LMAN1 and MCFD2 are the cause of a combined deficiency of FV and FVIII. MCFD2 binds these clotting factors and LMAN1 is the chaperone of MCFD2; the complex of both proteins transports FV and FVIII from the endoplasmic reticulum to the Golgi apparatus of the cell [24]. The activated partial thromboplastin time (aPTT) and prothrombin time (PT) are prolonged and the FV and FVIII levels range from 5% to 30%; bleeding with minor trauma, menorrhagia, and postpartum hemorrhage are reported in affected women [25]. Therapy includes desmopressin or recombinant FVIII concentrates to raise FVIII levels, and fresh frozen plasma to supplement FV [26].

Decreased levels of FIX are encountered in individuals with combined deficiencies of the vitamin K-dependent clotting factors [27]. Mutations in the genes for the vitamin K carboxylase or reductase prevent carboxylation of clotting factors II, VII, IX, and X, rendering them inactive and resulting in a bleeding phenotype. The differential diagnosis includes vitamin K deficiency, liver disease, and surreptitious ingestion of warfarin/rat poison. Treatment with vitamin K1 enables completion of clotting factor synthesis and ameliorates bleeding.

Hypothyroidism

Hypothyroid women and girls bruise easily and have menorrhagia. They have reduced levels of VWF and mildly decreased FVIII concentrations [28]. A systematic review in 2008 noted that the median value for VWF in 24 patients was only 28 U/dL, and FVIII ranged from 9 to 74 U/dL in 16 patients. These results are consistent with the diagnosis of aVWS [29]. A prospective study of 90 consecutive patients with overt hypothyroidism before or within 48 h of replacement therapy revealed that 33% met the criteria for aVWS [30]. The bleeding scores in these patients were negatively correlated with the levels of VWF. In addition, hypothyroid patients have evidence of excessive fibrinolytic activity [31]. Desmopressin administration is effective in controlling acute bleeding, and thyroid replacement is the definitive management [32].

Panhypopituitarism with central hypothyroidism is also associated with decreased levels of FVIII and VWF and has been described in a 9-year-old boy with multiple congenital anomalies and in a 40-year-old woman with Sheehan’s syndrome [33, 34].

Conclusions

A report of a decreased concentration of either FVIII or FIX in a female should raise the consideration of the possibility of hemophilia, especially if there is a history of easy bruising, excessive bleeding after dental or other surgery, and hemarthroses. A family history of bleeding episodes in one or more male relatives and marriages between cousins would be contributory. The differential diagnosis includes VWD in those with a decreased FVIII, as well as some of the other disorders described previously. Genetic studies should be obtained, not only of the patient but also of both parents, to identify the hemophilia-causing mutation and in whom it might have originated [3, 35]. Once a specific diagnosis is established, appropriate management for bleeding can be provided and genetic counselling initiated. Lastly, levels of FVIII and VWF might be decreased in acquired disorders such as autoimmune diseases, hypothyroidism, and panhypopituitarism, and unusual bleeding in these conditions should be fully investigated.

None to declare.

Conflict of Interest

None to declare.

Data Availability

The author declares that data supporting the findings of this study are available within the article.
==== Refs
References

1 Mannucci PM Tuddenham EG The hemophilias—from royal genes to gene therapy N Engl J Med 2001 344 23 1773 1779 10.1056/NEJM200106073442307 11396445
2 Center for Disease Control and Prevention. Community Counts Home, Factor VIII and Factor IX. Accessed at cdc.gov/ncbddd/hemophilia/index.html
3 Miller CH Bean CJ Genetic causes of haemophilia in women and girls Haemophilia 2021 27 2 e164 e179 10.1111/hae.14186 33314404
4 Lyu C Xue F Liu X Liu W Fu R Sun T Wu R et al Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing Haemophilia 2016 22 5 e427 434 10.1111/hae.12924 27292088
5 Cygan PH Kouides PA Regulation and importance of factor VIII levels in hemophilia A carriers Curr Opin Hematol 2021 28 5 315 322 10.1097/MOH.0000000000000667 34397591
6 Lyon MF X-chromosome inactivation and human genetic disease Acta Paediatr Suppl 2002 91 439 107 112 10.1111/j.1651-2227.2002.tb03120.x 12572852
7 Konkle BA Johnsen JM Wheeler M Watson C Skinner M Pierce GF My Life Our Future p Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project Haemophilia 2018 24 Suppl 6 87 94 10.1111/hae.13506 29878652
8 Garagiola I Mortarino M Siboni SM Boscarino M Mancuso ME Biganzoli M Santagostino E et al X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers Eur J Hum Genet 2021 29 2 241 249 10.1038/s41431-020-00742-4 33082527
9 Lusher JM McMillan CW Severe factor VIII and factor IX deficiency in females Am J Med 1978 65 4 637 648 10.1016/0002-9343(78)90852-5 309282
10 Clark KGA Haemophilic women Lancet 1973 1 7816 1388 1389 10.1016/s0140-6736(73)91713-3 4122775
11 Jackson JM Green RE Letter: Haemophilic women Lancet 1973 2 7833 845 10.1016/s0140-6736(73)90886-6 4126638
12 Sidonio RF Mili FD Li T Miller CH Hooper WC DeBaun MR Soucie M et al Females with FVIII and FIX deficiency have reduced joint range of motion Am J Hematol 2014 89 8 831 836 10.1002/ajh.23754 24838518
13 Israels MC Lempert H Gilbertson E Haemophilia in the female Lancet 1951 1 6670 1375 1380 10.1016/s0140-6736(51)92838-3 14842088
14 Kernoff PB Rizza CR Factor-VIII-related antigen in female haemophilia Lancet 1973 2 7831 734 10.1016/s0140-6736(73)92564-6 4125816
15 Kamiya T Koie K Ishiguro J Ogata K Classical haemophilia in girl with 46, XX karyotype and no family history of bleeding disorder Lancet 1977 1 8014 756 757 10.1016/s0140-6736(77)92206-1 66553
16 Hashmi KZ MacIver JE Delamore IW Christmas disease in a female Lancet 1978 2 8097 965 966 10.1016/s0140-6736(78)92528-x 81989
17 Blag C Serban M Ursu CE Popa C Traila A Jinca C Tomuleasa C et al Rare within Rare: A Girl with Severe Haemophilia A and Turner Syndrome J Clin Med 2023 12 23 7437 10.3390/jcm12237437 38068488
18 Gilchrist GS Hammond D Melnyk J Hemophilia A in a phenotypically normal female with XX/XO mosaicism N Engl J Med 1965 273 26 1402 1406 10.1056/NEJM196512232732602 5850038
19 Nisen P Stamberg J Ehrenpreis R Velasco S Shende A Engelberg J Karayalcin G et al The molecular basis of severe hemophilia B in a girl N Engl J Med 1986 315 18 1139 1142 10.1056/NEJM198610303151806 3093864
20 Mason JA Aung HT Nandini A Woods RG Fairbairn DJ Rowell JA Young D et al Demonstration of a novel Xp22.2 microdeletion as the cause of familial extreme skewing of X-inactivation utilizing case-parent trio SNP microarray analysis Mol Genet Genomic Med 2018 6 3 357 369 10.1002/mgg3.378 29490426
21 Lulla RR Allen GA Zakarija A Green D Transplacental transfer of postpartum inhibitors to factor VIII Haemophilia 2010 16 1 14 17 10.1111/j.1365-2516.2009.02049.x 19500168
22 Green D Hemophilia and von Willebrand Disease Academic Press San Diego 2018 192 196
23 Haberichter SL von Willebrand factor propeptide: biology and clinical utility Blood 2015 126 15 1753 1761 10.1182/blood-2015-04-512731 26215113
24 Zhang Y Liu Z Zhang B Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII Blood Adv 2023 7 7 1286 1296 10.1182/bloodadvances.2022008788 36490287
25 Palla R Peyvandi F Shapiro AD Rare bleeding disorders: diagnosis and treatment Blood 2015 125 13 2052 2061 10.1182/blood-2014-08-532820 25712993
26 Spreafico M Peyvandi F Combined FV and FVIII deficiency Haemophilia 2008 14 6 1201 1208 10.1111/j.1365-2516.2008.01845.x 19141160
27 Napolitano M Mariani G Lapecorella M Hereditary combined deficiency of the vitamin K-dependent clotting factors Orphanet J Rare Dis 2010 5 21 10.1186/1750-1172-5-21 20630065
28 Rogers JS 2nd Shane SR Jencks FS Factor VIII activity and thyroid function Ann Intern Med 1982 97 5 713 716 10.7326/0003-4819-97-5-713 6814317
29 Manfredi E van Zaane B Gerdes VE Brandjes DP Squizzato A Hypothyroidism and acquired von Willebrand's syndrome: a systematic review Haemophilia 2008 14 3 423 433 10.1111/j.1365-2516.2007.01642.x 18218015
30 Stuijver DJ Piantanida E van Zaane B Galli L Romualdi E Tanda ML Meijers JC et al Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study Haemophilia 2014 20 3 326 332 10.1111/hae.12275 24118466
31 Verkleij CJ Stuijver DJ van Zaane B Squizzato A Brandjes DP Buller HR Meijers JC et al Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia Thromb Haemost 2013 109 2 214 220 10.1160/TH12-07-0525 23197299
32 Erfurth EM Ericsson UB Egervall K Lethagen SR Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism Clin Endocrinol (Oxf) 1995 42 4 373 378 10.1111/j.1365-2265.1995.tb02645.x 7750191
33 Setian N Tanaka CM Damiani D Dichtchekenian V Carneiro JD D'Amico EA Hypopituitarism, deficiency of factors V and VIII and von Willebrand factor: an uncommon association J Pediatr Endocrinol Metab 2002 15 3 331 333 10.1515/jpem.2002.15.3.331 11926206
34 Oliveira MC Kramer CK Marroni CP Leaes CG Viana L Roithman S Schmaedecke A et al Acquired factor VIII and von Willebrand factor (aFVIII/VWF) deficiency and hypothyroidism in a case with hypopituitarism Clin Appl Thromb Hemost 2010 16 1 107 109 10.1177/1076029608319948 18550587
35 Vidal F State of the art of genetic studies in hemophilia carriers Blood Coagul Fibrinolysis 2020 31 1S S4 S5 10.1097/MBC.0000000000000992 33351493
